Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Targeting the key autophagy protease ATG4B in BCR-ABL+ human leukemia

FY 2017-18

Summary
Blood cancer (leukemia) is common, with ~55,000 cases expected in the United States and Canada in 2017.According toNational Cancer Institute (US),the 5-year survival rate for leukemia is 56%. Durg resistance and relapse pose significant challenges. Life-long treatment is required, with potential side-effects and a high cost. Blood cancer cells generally respond to drug therapy at the onset, but the drugs lose their effectiveness after 6-12 months. This is mainly due to the inability of current therapies to eradicate leukemic stem cells, which maintain the potential for relapse. There is thus an urgent need to develop new therapies that specifically targetleukemic stem cells so that these cells can be eliminated. Dr. Jiang's lab has found that ATG4B, a novel drug target and key driver in autophagy, displays abnormal activity in leukemic stem cells, particularly in drug-resistant patients. However, there is currently no drugs for autophagy inhibition that are approved as therapeutics. Several promising new drugs have been developed that specifically target ATG4B in blood cancer stem cells. Combining these with current anti-cancer drugs more effectively inhibits leukemic stem cell growth in culture than single drug treatment. This treatment strategy has minimal side-effects on normal blood stem cells. My study will investigate if this combination therapycan more effectively eradicate leukemic stem cells using animal models, which can reduce the infiltration of leukemic cells and prevent leukemia development. This study has great implication to blood cancer treatment. If successful, it will provide ultimate proof-of-concept for the development of more effective therapies with fewer side effects than currently used therapies.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
386605
Name
Shen Yueyang
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Targeting the key autophagy protease ATG4B in BCR-ABL+ human leukemia
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Atg4b; Atg4b Inhibitors; Autophagy; Bcr-Abl; Caloric Restriction; Chronic Myeloid Leukemia; Drug Resistance; Leukemic Stem Cell; Tyrosine Kinase Inhibitors; Xeno-Transplant Mouse Model
Abstract
Blood cancer (leukemia) is common, with ~55,000 cases expected in the United States and Canada in 2017.According toNational Cancer Institute (US),the 5-year survival rate for leukemia is 56%. Durg resistance and relapse pose significant challenges. Life-long treatment is required, with potential side-effects and a high cost. Blood cancer cells generally respond to drug therapy at the onset, but the drugs lose their effectiveness after 6-12 months. This is mainly due to the inability of current therapies to eradicate leukemic stem cells, which maintain the potential for relapse. There is thus an urgent need to develop new therapies that specifically targetleukemic stem cells so that these cells can be eliminated. Dr. Jiang's lab has found that ATG4B, a novel drug target and key driver in autophagy, displays abnormal activity in leukemic stem cells, particularly in drug-resistant patients. However, there is currently no drugs for autophagy inhibition that are approved as therapeutics. Several promising new drugs have been developed that specifically target ATG4B in blood cancer stem cells. Combining these with current anti-cancer drugs more effectively inhibits leukemic stem cell growth in culture than single drug treatment. This treatment strategy has minimal side-effects on normal blood stem cells. My study will investigate if this combination therapycan more effectively eradicate leukemic stem cells using animal models, which can reduce the infiltration of leukemic cells and prevent leukemia development. This study has great implication to blood cancer treatment. If successful, it will provide ultimate proof-of-concept for the development of more effective therapies with fewer side effects than currently used therapies.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Shen, Yueyang
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~